Dihydroergotoxine tablets

 Dihydroergotoxine tablets

Class: Psychotherapeutic agent
Available in:- Tablets, oral 1 mg
- Tablets, sublingual 0.5 mg
- Tablets, sublingual 1 mg
- Liquid 1 mg/mL
- Tablets, oral 1 mg
- Tablets, sublingual 0.5 mg
- Tablets, sublingual 1 mg

Generics: Dihydroergotoxine tablets
 
 Pharmacokinetics

Absorption: Approximately 25% is absorbed; approximately 50% is removed by the first-pass metabolism. T _max is 1.5 to 3 h.

Distribution: Excreted in breast milk.

Metabolism: Undergoes first-pass metabolism.

Elimination: The t _½ is approximately 2.6 to 5.1 h (unchanged ergoloid in the plasma).

Indications and Usage
Treatment of age-related decline in mental capacity, primary progressive dementia, Alzheimer dementia, multi-infarct dementia and senile onset.

Contraindications:
Hypersensitivity to Ergoloid mesylates or other ergot alkaloids; acute or chronic psychosis.

Dosage and Administration

Adults: PO/SL 1 to 2 mg 3 times daily (up to 12 mg/day has been used).

General Advice: Instruct patient to allow SL tablets to completely dissolve under tongue; do not allow patient to swallow, crush, or chew tablet.

Storage/Stability: Store in tightly closed, light-resistant container at room temperature.

Drug Interactions: None well documented.

Laboratory Test Interactions: None well documented.

Adverse Reactions:

Cardiovascular: Orthostatic hypotension; bradycardia.

Dermatologic: Rash.

GI: Transient nausea; GI disturbances; sublingual irritation.

Precautions: Pregnancy
Pregnancy category undetermined.
Lactation: Undetermined.
Children: Safety and efficacy not established.
Hepatic Function: Elimination of drug may be affected.
Special Risk Patients: Administer drug with caution to patients with history of bradycardia or hypotension.

Overdosage /Symptoms: Headache, flushing, anorexia, nausea, vomiting, abdominal cramps, nasal congestion, impaired vision, dizziness, fainting.